NAD+, NMN, NR, and IV NAD: What the Research Actually Shows

NAD vs NAD+: same molecule, different state

The naming convention is genuinely confusing if you're encountering it for the first time. NAD stands for nicotinamide adenine dinucleotide — a coenzyme used by hundreds of enzymes across nearly every cell in your body. It exists in two interconvertible forms:

• NAD+ — the oxidized form. This is what enzymes use as an electron acceptor. The "+" denotes the positive charge on the nitrogen in the nicotinamide ring.
• NADH — the reduced form. NAD+ becomes NADH when it accepts two electrons and a proton from a substrate.

NAD+ and NADH are a redox pair — the same underlying molecule shuttling electrons. When you see "NAD" used loosely, the writer usually means NAD+ specifically, because that's the form most relevant to the metabolic and longevity claims being made. The cellular pool of NAD+ is what declines with age and what supplements aim to raise.

So when someone says "NAD declines with age" or "NAD supplements," they almost always mean NAD+ specifically. The two terms have collapsed into near-synonyms in the consumer health space, but the biochemistry is more precise than that.

Why NAD+ matters for aging biology

NAD+ is the cofactor for at least three classes of enzymes that matter for aging:

• Sirtuins — a family of seven enzymes (SIRT1 through SIRT7) that regulate metabolism, DNA repair, mitochondrial function, and gene expression. Sirtuins consume NAD+ as a substrate; their activity scales with NAD+ availability.
• PARPs (poly-ADP-ribose polymerases) — DNA-repair enzymes that also consume NAD+. PARP activity increases with DNA damage; under heavy DNA damage, PARPs can deplete cellular NAD+ pools.
• CD38 — a NAD+-consuming enzyme on immune cells. CD38 expression increases with aging, contributing to the age-related NAD+ decline observed in tissue samples.

The textbook longevity story goes like this: cellular NAD+ declines with age. Lower NAD+ means lower sirtuin activity, impaired DNA repair, and reduced mitochondrial function. Restore NAD+ and you restore the biology — potentially slowing aging.

This story has a real biological foundation. NAD+ does decline in many aged tissues. Sirtuins do depend on NAD+. Restoring NAD+ in old animals can produce striking improvements in mitochondrial function, exercise capacity, and certain biomarkers. The gap between this and "taking NMN reverses your aging" is the gap between mechanism and outcome — and it's that gap the supplement marketing routinely papers over.

The forms, decoded

NAD+ supplements come in radically different chemical forms with substantially different evidence bases. The terminology is dense and the marketing isn't always honest about what you're actually buying. Here's the field map.

Niacin (nicotinic acid)

The cheapest and oldest NAD+ precursor. Niacin is vitamin B3 — known to medicine for nearly a century. It raises NAD+ levels effectively because it enters one of the two NAD+ biosynthesis pathways (the Preiss-Handler pathway). Niacin has decades of clinical data, including its old use as a lipid-lowering agent before statins displaced it.

The practical drawback is flushing — niacin causes substantial vasodilation, producing intense warmth, redness, and itching that some users find intolerable. Sustained-release formulations reduce flushing but introduce a small hepatotoxicity risk at high doses. Most longevity-focused users skip niacin because of the flushing — but evidence-wise, it's a real and inexpensive way to raise NAD+.

Nicotinamide (NAM)

The amide form of B3, also widely available. Nicotinamide raises NAD+ via a different route (the salvage pathway). It avoids the flushing issue of niacin. However, nicotinamide has a relevant problem for longevity-focused users: at high doses, it inhibits sirtuins — the very enzymes the NAD+ rationale relies on. This is paradoxical and well-documented in the biochemistry literature. For this reason, nicotinamide is generally not recommended for NAD+-for-longevity protocols, even though it does raise blood NAD+ levels.

NR (Nicotinamide Riboside)

The form with the most controlled human trial data. NR is a more recently-identified NAD+ precursor, commercialized primarily by ChromaDex under the brand name Niagen (and licensed for products like Tru Niagen and Life Extension formulations). Multiple Phase 1/2 trials have shown that NR reliably raises blood NAD+ levels at doses of 250-1000 mg/day, with a generally favorable safety profile. The FDA has designated NR as Generally Recognized as Safe (GRAS) for use in food and supplements.

Beyond the biomarker effect, NR trials have shown modest signals on blood pressure, muscle insulin sensitivity in older adults, and some inflammatory markers. Most effect sizes are modest and several trials have been negative. No human trial of NR has demonstrated extended lifespan or any aging-specific outcome — the trials are short, the endpoints are surrogate markers, and the field is still building the case.

NMN (Nicotinamide Mononucleotide)

The form most heavily promoted by David Sinclair, the Harvard aging-research professor. NMN is one biosynthetic step closer to NAD+ than NR — in the standard pathway, NR is converted to NMN, which is then converted to NAD+. This sequence is the basis of the claim that NMN is "more efficient" than NR, though the actual rate-limiting steps and tissue-specific kinetics complicate this picture.

Human NMN trials have accumulated rapidly through 2022-2025, mostly small (20-100 participants) and short (4-12 weeks). They consistently show that NMN raises blood NAD+ levels — the biomarker effect is robust. Beyond that, signals are mixed and modest: some show improvements in muscle function, aerobic capacity, sleep, and insulin sensitivity; others are negative on similar endpoints.

NMN has had an unusual regulatory journey. In late 2022, the FDA effectively excluded NMN from the dietary supplement category by ruling that it had been studied as a drug first (under a pending IND), which under current law prevents subsequent supplement sale. This created enormous market disruption — many large brands had to reformulate or stop selling NMN. The legal and regulatory status has continued to shift through 2024-2025 with industry challenges; as of 2026 the picture remains contested. Practically, NMN remains widely available through various channels even where it's not technically allowed as a dietary supplement.

Oral "NAD+" supplements (including "buffered NAD+")

These are products that claim to deliver NAD+ itself, not a precursor. The biological problem is that NAD+ is a relatively large, charged molecule that's poorly absorbed across the intestinal wall and substantially degraded by digestive enzymes. Direct oral NAD+ has not been shown to meaningfully raise tissue NAD+ levels through systemic absorption — the molecule largely gets broken down before reaching circulation. Even if some makes it through, it's likely degraded to nicotinamide and other simpler components that you could have just taken directly.

"Buffered NAD+" products extend this with claims about pH-buffering to protect the molecule from stomach acid. The buffering may marginally improve survival of intact NAD+ through the stomach, but the deeper bioavailability problems — molecular size, charge, intestinal degradation, and first-pass metabolism — remain unresolved. There are essentially no published controlled human trials demonstrating that oral or buffered NAD+ raises tissue NAD+ better than equivalent doses of NR, NMN, or even plain nicotinamide. The marketing is substantial; the trial data isn't there.

The honest framing: if you swallow an "NAD+" tablet, you're probably mostly absorbing nicotinamide after digestive breakdown. You'd get similar biology at much lower cost from generic nicotinamide or niacin.

IV NAD+ infusions

The clinical practice of administering NAD+ directly intravenously, typically delivered over several hours at doses of 250-1500 mg per session in a clinic setting. IV bypasses the absorption problem entirely — the molecule enters circulation directly. Subjective reports from users tend to be dramatic: increased energy, cognitive clarity, mood improvement, and a sense of "feeling reset" after treatment. Some users report cravings reduction in addiction recovery contexts (this is one of the original clinical applications of IV NAD+, going back decades).

The evidence base is genuinely thin relative to the cost and the subjective effect size. There are no large controlled trials of IV NAD+ for longevity, healthspan, addiction recovery, or essentially any other clinical endpoint. The available literature is dominated by case reports, observational studies, small pilots, and clinical experience reports from the practitioners offering the treatment. The mechanism by which IV NAD+ produces such robust subjective effects — given that exogenous NAD+ should largely be metabolized to nicotinamide and other components peripherally before reaching tissues — is not fully characterized in the literature.

This is a real puzzle. Either IV NAD+ produces effects through mechanisms not well understood (peripheral signaling, immune modulation, vagal effects, placebo response of substantial magnitude, or something else), or the subjective effects are produced by something other than intact tissue NAD+ delivery. The clinical practice has substantially outrun the controlled trial data, which means users are making decisions based on practitioner experience and personal response rather than RCT evidence.

Cost is also a real factor. IV NAD+ sessions typically run $300-1500 each in private clinics, often used as a series of 5-10 sessions, making the total cost meaningfully greater than years of oral precursor supplementation.

Subcutaneous, sublingual, intranasal, and injectable NAD+

These delivery routes attempt to bypass the digestive absorption problem without requiring an IV infusion. The evidence picture varies:

• Subcutaneous injectable NAD+ — the most-discussed alternative to IV in research-peptide communities. Some users self-administer subcutaneous NAD+ to attempt similar effects to IV at lower cost. The pharmacokinetics of SC NAD+ are poorly characterized in the published literature; absorption and tissue distribution have not been well studied.
• Sublingual NAD+ — claims to bypass first-pass metabolism through absorption across the oral mucosa. The mucosa is permeable to certain molecules but NAD+ is large enough that sublingual bioavailability is likely modest. Published evidence for sublingual NAD+ products is essentially absent.
• Intranasal NAD+ — uncommon, sometimes marketed for cognitive applications. Like sublingual, the published evidence is essentially absent.

Across these less-common routes, the pattern is the same: real bioavailability concerns, no robust controlled trial data, substantial marketing claims that aren't backed by the kind of pharmacokinetic and outcome studies that would support the cost differential over established oral precursors.

What human trials actually show

Several dozen published human trials have now examined NAD+ precursor supplementation, primarily NR and NMN, with smaller bodies of evidence for niacin and other forms. The pattern across this literature is reasonably consistent.

The biomarker effect is settled. NR at 250-1000 mg/day reliably raises blood NAD+ levels by approximately 40-150% over baseline within weeks. NMN at 250-1000 mg/day produces similar effects. Niacin at lower doses also raises NAD+. This is well-replicated and is no longer in scientific dispute.

Modest functional signals exist. Trials have shown small-to-moderate improvements in:

• Muscle insulin sensitivity in older adults (NR)
• Aerobic capacity in middle-aged sedentary adults (NMN)
• Walking distance and grip strength in older adults (NMN, some trials)
• Blood pressure in subjects with elevated baseline (NR)
• Markers of cardiovascular health and arterial stiffness (NR, mixed)
• Subjective sleep quality (NMN, some trials)

Effect sizes in these trials are generally modest — typical improvements are in the range of 5-15% over placebo on the affected endpoints. Several trials have been null. The clinical significance of these effects, even when present, is unclear.

The aging outcome data does not exist. No human trial has tested NAD+ precursor supplementation against any aging-relevant outcome — lifespan, healthspan, frailty incidence, age-related disease onset — over a long enough timeframe to detect such effects. The trials we have are typically 4-12 weeks long, sometimes extending to 6-12 months, with surrogate endpoints. The leap from "raises NAD+ levels and modestly improves some functional measures" to "slows aging" is currently unsupported by direct evidence.

Animal model evidence is more dramatic but is animal model evidence. Rodent studies have shown impressive results — improved mitochondrial function, exercise capacity, glucose homeostasis, and in some studies extended lifespan with NMN or NR. These results are real and form the mechanistic basis of clinical interest. They are also routinely overgeneralized to humans by marketing copy in ways that the actual trial data doesn't support.

The Sinclair / NMN discourse

David Sinclair, the Harvard genetics and aging researcher, has been the most visible public advocate for NMN supplementation specifically. His advocacy has shaped consumer perception of NAD+ supplements more than any other single factor. Understanding the context helps calibrate the public discourse.

Sinclair is a credible scientist with substantial contributions to sirtuin biology and the broader NAD+/aging field. His laboratory has produced a meaningful share of the foundational mouse work establishing the NAD+/sirtuin/longevity axis. His public communication, however, has frequently outrun what the trial data actually shows. Statements suggesting NMN has reversed biological age, dramatic claims about personal experience, and the implicit framing that taking NMN is an evidence-based longevity intervention rather than a biomarker-affecting bet — these have been criticized both inside and outside the field for getting ahead of the controlled evidence.

Sinclair also has financial interests in companies commercializing NMN and related products, which is appropriate to acknowledge as context for his public advocacy. This doesn't invalidate his scientific work, but it should inform how readers weigh his consumer-directed claims relative to the controlled trial data.

The honest framing: NMN is a reasonable bet if you're inclined to act on the NAD+/aging hypothesis. The evidence base is closer to "interesting mechanism plus biomarker effect" than "validated aging intervention." Anyone telling you with high confidence that NMN extends human lifespan is overstating what the data shows.

Which form the evidence most supports

Sorted by evidence strength for the biomarker effect (raising blood NAD+):

1. NR (nicotinamide riboside) — most controlled human trial data, FDA-recognized as safe, reliable biomarker effect, modest signals on some functional endpoints. The most-defensible bet if you're following the evidence.
2. NMN (nicotinamide mononucleotide) — rapidly accumulating but smaller trial base. Similar biomarker effect, similar functional signals, contested regulatory status. A reasonable alternative to NR, particularly if cost or availability differs.
3. Niacin (nicotinic acid) — substantial historical data, raises NAD+ effectively, cheapest option. The flushing limits compliance for many users. The most cost-effective bet if you tolerate the flushing.
4. Nicotinamide (NAM) — raises NAD+ but inhibits sirtuins at higher doses, which undermines the longevity rationale. Not recommended for NAD+-for-longevity use specifically.
5. IV NAD+ — robust subjective effects, no controlled outcome data, very expensive. Falls into the "trying it because the experience reports are dramatic" category rather than the "following the evidence" category.
6. Oral "NAD+" and "buffered NAD+" — bioavailability problems and absence of controlled trial data make these the weakest evidence-supported options. The substantial marketing claims are not backed by trial data demonstrating superiority over established precursors.
7. Subcutaneous, sublingual, intranasal NAD+ — minimal published evidence; substantial cost premium; not currently supported by the evidence base.

What we still don't know

The open questions in NAD+ supplementation are substantial and largely concentrated at the outcome end of the chain:

• Does raising NAD+ produce meaningful clinical outcomes? The biomarker effect is real. The translation to clinical benefit — measured by hard endpoints, not surrogate markers — is largely unproven.
• Are the modest functional improvements meaningful? Even when trials show improvements in walking distance or grip strength, the magnitudes are small. Whether such effects accumulate into healthspan extension over years is unknown.
• Is there a dose-response curve, and where is the optimum? Most trials have used doses in the 250-1000 mg/day range. Whether higher doses produce proportionally greater effects, plateau, or produce diminishing returns is unclear.
• Are there long-term safety concerns? Short-term safety in trials has been good. Chronic supplementation over years to decades has not been studied, and theoretical concerns exist (impact on sirtuin signaling, methyl-donor pool depletion at high doses, possible interaction with cancer biology) that the available trial data is too short to address.
• Why does IV NAD+ produce such dramatic subjective effects? The pharmacokinetic story of IV NAD+ — most of which should be peripherally metabolized to simpler components before reaching tissues — doesn't obviously predict the reported subjective effects. Either the mechanism is different than commonly described, or the effects are produced by something other than tissue NAD+ delivery. This is a real puzzle worth more research.
• Does the form matter beyond biomarker effect? If NR and NMN both raise blood NAD+ comparably, do they produce equivalent downstream effects? Or do tissue-specific kinetics, transporter biology, or other differences matter clinically? Largely unresolved.

Practical considerations

If you're inclined to try a NAD+ precursor based on the biology: NR has the cleanest evidence story. Standard doses in trials are 250-500 mg/day, sometimes up to 1000 mg/day for clinical-research contexts. Cost is typically $40-80/month at retail.

If cost is the deciding factor and you can tolerate flushing: Niacin at 100-500 mg/day raises NAD+ at perhaps 1-5% of the cost of NR. Slow-release formulations reduce flushing but introduce a small hepatotoxicity risk at higher doses; immediate-release with food is often a tolerable workaround once you adapt.

If you've already invested in NMN and want to know if you should switch: Probably not worth switching back and forth. Both forms have similar biomarker effects in available trials. The regulatory situation makes NMN harder to source legitimately, but if you have a quality source, the molecular-level difference is unlikely to be clinically meaningful at typical doses.

If you're considering IV NAD+: Be honest with yourself about what you're buying — primarily a subjective experience and the framework of an aging-medicine clinical visit. The evidence for outcome benefit is not what supports the cost. If the subjective experience is valuable to you, that's a defensible reason; if you're treating it as an evidence-based longevity intervention, the evidence isn't there.

If you're encountering "buffered NAD+" or other novel-delivery oral products: The marketing is much louder than the evidence. Generic nicotinamide is dramatically cheaper and produces similar biology — though at the cost of the sirtuin-inhibition concern at higher doses. Generic NR is the better-supported choice at moderate cost premium.

Across all forms: NAD+ supplementation is a biomarker-affecting bet on an interesting biological hypothesis, not a proven aging intervention. The well-supported foundations of healthspan — sleep, exercise, nutrition, addressing cardiovascular and metabolic risk factors, social connection — produce vastly larger expected benefits than any NAD+ precursor at any dose. The peptide and supplement layer is appropriate only as adjunct to the foundation, not as substitute for it.

The honest read

NAD+ supplementation is one of the more interesting bets in the broader longevity space. The biology is real, the biomarker effect is replicated, and the underlying hypothesis — that maintaining NAD+ pools matters for aging — has a coherent mechanistic foundation. The mismatch is between the strength of the evidence and the volume of the marketing.

If you want to follow the evidence: NR at standard doses is the most-supported choice, with NMN as a reasonable alternative depending on cost and availability. If you want to follow the cost-effectiveness logic: niacin is dramatically cheaper and works. If you're tempted by IV, buffered, or specialty oral NAD+ products: understand you're paying a premium for delivery routes that have not been demonstrated to outperform the established precursors.

The most important framing: raising blood NAD+ is not the same as extending healthspan. It is a biomarker effect with a plausible mechanistic connection to aging biology. Whether that biomarker effect translates to clinical outcomes meaningful enough to justify the time, cost, and complexity of supplementation is unsettled. Acting on the hypothesis is reasonable if you understand it as a hypothesis; treating it as evidence-based longevity medicine is overstating what the data shows.